DUPILUMAB improved disease severity, quality of life, and adherence in children with atopic dermatitis.
Dupilumab in Pediatric Atopic Dermatitis
Dupilumab demonstrated robust efficacy, durable benefits, and a favorable safety profile in children with moderate-to-severe atopic dermatitis, according to a systematic review of pediatric evidence.
Atopic dermatitis is a chronic, relapsing inflammatory skin disease that disproportionately affects children and can create substantial physical, psychological, and social burden. Although biologic therapies have reshaped management in adults, pediatric-specific evidence remains more limited. Dupilumab, an interleukin 4 receptor alpha antagonist that inhibits interleukin 4 and interleukin 13 signaling, is currently the only FDA-approved biologic for pediatric atopic dermatitis.
Disease Severity and Quality of Life Improved
The review followed PRISMA 2020 guidance and included randomized controlled trials, open-label extensions, observational studies, case series, and case reports. Investigators searched PubMed, Embase, and the Cochrane Library from inception to August 10, 2024, identifying 20 eligible studies after screening 1,576 records. The included evidence involved approximately 1,200 children, ranging from 5 months to 12 years of age.
Across study designs, dupilumab was associated with rapid and sustained improvements in disease severity. Mean Eczema Area and Severity Index reductions ranged from 62% to 92%, while EASI-75 response rates ranged from 53% to 94% within 16 to 52 weeks. Benefits were assessed where possible across children aged 6 months to 5 years and those aged 6 to 11 years. Some studies reported numerically higher or faster responses in children younger than 6 years, although findings were inconsistent and limited by differences in disease duration, dosing, and sample size.
Quality of life gains were also substantial. Children’s Dermatology Life Quality Index scores decreased by up to approximately 89%, and sleep improvement was marked, suggesting benefits beyond skin clearance alone.
Safety and Adherence Findings
Adverse events were generally mild. Conjunctivitis was the most common event, occurring in 0% to 20% of participants, while herpesvirus infections and injection-site reactions were rare. Laboratory abnormalities, including eosinophilia and alkaline phosphatase elevation, were typically asymptomatic and transient.
Adherence was high, reaching at least 90% in most cohorts, with low discontinuation rates. However, the authors noted that predominantly observational and uncontrolled study designs, heterogeneity in outcomes and follow-up, and small sample sizes in several cohorts limit certainty.
Overall, the findings support dupilumab as a systemic option for children with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy. Future research should clarify long-term outcomes, comparative effectiveness against conventional immunosuppressants, age-stratified response patterns, and cost effectiveness across healthcare settings.
Reference
Surma J et al. Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review. Clin Drug Investig. 2026;doi: 10.1007/s40261-026-01573-9.
Featured Image: Monkey Business on Adobe Stock.
- Author:
